Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer
Jacob J. Orme, Fadi Taza, Navonil De Sarkar, Alok K. Tewari, Syed Arsalan Ahmed Naqvi, Irbaz Bin Riaz, Daniel S. Childs, Noha Omar, Nabil Adra, Ryan Ashkar, Heather H. Cheng, Michael T. Schweizer, Alexandra Sokolova, Neeraj Agarwal, Pedro C. Barata, Oliver Sartor, Diogo Assed Bastos, Òren Smaletz, Jacob E. Berchuck, Heather M. McClure, Mary‐Ellen Taplin, Rahul Aggarwal, Cora N. Sternberg, Panagiotis J. Vlachostergios, Ajjai Alva, Niven Mehra, Peter S. Nelson, Justin H. Hwang, Scott M. Dehm, Qian Shi, Zoe Fleischmann, Ethan S. Sokol, Andrew Elliott, Haojie Huang, Alan H. Bryce, Catherine H. Marshall, Emmanuel S. Antonarakis
Topics & Concepts
MedicinePARP inhibitorHazard ratioProstate cancerInternal medicineOncologyProportional hazards modelPoly ADP ribose polymeraseClinical endpointCancerConfidence intervalClinical trialPolymeraseBiologyGeneticsGeneProstate Cancer Treatment and ResearchPARP inhibition in cancer therapyProstate Cancer Diagnosis and Treatment